Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denise Treue

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 22, 2019
Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic optionsPhilipp Jurmeister, Claudia Vollbrecht, Anke Behnke, et al.
Science Translational Medicine|September 13, 2019
Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastasesPhilipp Jurmeister, Michael Bockmayr, Philipp Seegerer, et al.
The Journal of Pathology. Clinical Research|November 12, 2020
TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanismsMaren Schmiester, Anna Dolnik, Uwe Kornak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
<i>TP53</i> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 TrialMarianne Sinn, Bruno V Sinn, Denise Treue, et al.
International Journal of Cancer|May 30, 2020
Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCCClemens Messerschmidt, Benedikt Obermayer, Konrad Klinghammer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast CancerBruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical TrialsPaul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2019
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto TrialSibylle Loibl, Denise Treue, Jan Budczies, et al.
NPJ Breast Cancer|April 13, 2026
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancerMarion T Van Mackelenbergh, Nicole Pfarr, Karsten Weber, et al.
Cancer Gene Therapy|June 8, 2024
Proteomic profiling reveals ACSS2 facilitating metabolic support in acute myeloid leukemiaLiliana H Mochmann, Denise Treue, Michael Bockmayr, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Lung Cancer (Amsterdam, Netherlands)|October 22, 2019
Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic optionsPhilipp Jurmeister, Claudia Vollbrecht, Anke Behnke, et al.
Science Translational Medicine|September 13, 2019
Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastasesPhilipp Jurmeister, Michael Bockmayr, Philipp Seegerer, et al.
The Journal of Pathology. Clinical Research|November 12, 2020
TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanismsMaren Schmiester, Anna Dolnik, Uwe Kornak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
<i>TP53</i> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 TrialMarianne Sinn, Bruno V Sinn, Denise Treue, et al.
International Journal of Cancer|May 30, 2020
Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCCClemens Messerschmidt, Benedikt Obermayer, Konrad Klinghammer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast CancerBruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical TrialsPaul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2019
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto TrialSibylle Loibl, Denise Treue, Jan Budczies, et al.
NPJ Breast Cancer|April 13, 2026
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancerMarion T Van Mackelenbergh, Nicole Pfarr, Karsten Weber, et al.
Cancer Gene Therapy|June 8, 2024
Proteomic profiling reveals ACSS2 facilitating metabolic support in acute myeloid leukemiaLiliana H Mochmann, Denise Treue, Michael Bockmayr, et al.
Pageof 3